- **Revenue Growth**: 19.8% YoY to $589M, driven by FIRDAPSE (+17%) and AGAMREE (+154%).
- **2026 Outlook**: FIRDAPSE up 21-26%, AGAMREE up 19-28%, FYCOMPA down to $40-45M.
- **Strategic Initiatives**: 600+ LEMS patients in pipeline, 21% VGCC test growth, and 12% reduction in FIRDAPSE discontinuations.
- **Financial Strength**: $709M cash, Non-GAAP EPS $2.72, and 37% YoY cash growth.
- **Pipeline Potential**: SUMMIT trial enrollment for AGAMREE, Phase 1a immunosuppression study, and 100+ BD opportunities.

**【CEO Summary Section】**
- **2025 Revenue Growth**: Total revenue reached $589 million, up 19.8% YoY, exceeding guidance. FIRDAPSE and AGAMREE drove 20.3% and 154.3% growth, respectively.
- **2026 Guidance**: FIRDAPSE ($435M-$450M), AGAMREE ($140M-$150M), FYCOMPA ($40M-$45M). Focus on idiopathic LEMS (30% penetration) and cancer-associated LEMS (under 10%).
- **Business Development**: 100+ assessments in 2025, prioritizing $500M+ rare disease assets with clear regulatory paths.

**【CFO Financial Commentary】**
- **2025 Financials**: GAAP net income $214.3M ($1.68 EPS), Non-GAAP $346.2M ($2.72 EPS). Cash increased to $709.2M, up 37% YoY.
- **2026 Outlook**: FIRDAPSE gross-to-net impact from IRA; AGAMREE royalties escalating with sales. R&D spend expected to rise to $17.5M-$22.5M for life cycle management.
- **Cost Management**: SG&A up 11.6% YoY due to headcount and business dev, but 5% of revenue saved via operational efficiency.

**【Q&A Key Highlights】**
- **FIRDAPSE Growth Drivers**: 600+ identified LEMS patients (50% conversion rate), 21% YoY VGCC test growth, and 12% reduction in discontinuations via pharmacy program.
- **AGAMREE Momentum**: 85%+ reimbursement rate, 45% of patients switching from prednisone/EMFLAZA, and SUMMIT trial enrollment on track for long-term data.
- **Business Development**: 90% inbound deals in 2025; 2026 focus on low-risk, near-market assets with $500M+ peak sales potential.
- **FYCOMPA Transition**: 2026 sales expected to remain meaningful ($40M-$45M) despite generics entry.


Catalyst Pharmaceuticals, Inc.(CPRX)-20260226-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 revenue up 15.3% to $148.4M, driven by FIRDAPSE (+16.2%), AGAMREE (+115.2%), and FYCOMPA (+17.4%).
- **Strategic Expansion**: Cancer-associated LEMS testing and NCCN guideline updates position 2026 growth; AGAMREE adoption at 85% of DMD centers.
- **Financial Strength**: $689.9M cash, no debt; Non-GAAP net income $86.1M (+21.4% YoY).
- **Risk Management**: FYCOMPA generic erosion expected, but 85% patient retention; FIRDAPSE IP defense ongoing.
- **Share Buyback**: $200M program announced to return capital to shareholders.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 total revenue of $148.4 million, up 15.3% YoY, driven by FIRDAPSE ($92.2M, +16.2%), AGAMREE ($32.4M, +115.2%), and FYCOMPA ($23.8M, +17.4%).
- **Strategic Initiatives**: Expanded oncology-focused LEMS testing, NCCN guideline updates, and $200M share buyback program announced.
- **Guidance Update**: Full-year 2025 revenue raised to $565-585M, with FIRDAPSE ($355-360M), AGAMREE ($105-115M), and FYCOMPA ($100-110M) targets.
- **Cash Position**: $689.9M cash, no debt, supporting R&D and business development.

**【CFO Financial Commentary】**
- **Profitability**: GAAP net income $52.8M ($0.42/share), +20.3% YoY; Non-GAAP net income $86.1M ($0.68/share), +21.4% YoY.
- **Cost Management**: SG&A expenses $47.5M (+3.5% YoY), R&D $2.7M, reflecting disciplined spending.
- **Liquidity**: Generated $163.8M cash from operations, supporting long-term growth.
- **One-Time Cash Impact**: $24.9M accelerated payment from a customer contract affecting Q3 timing.

**【Q&A Highlights】**
- **FIRDAPSE Oncology Expansion**: 90% of cancer-associated LEMS patients undiagnosed; NCCN guideline adoption and VGCC testing initiatives driving 2026 growth.
- **FYCOMPA Brand Loyalty**: 25.8% YoY decline due to generics, but 85% patient retention; expect continued erosion as more generics enter.
- **AGAMREE Adoption**: 43% of DMD centers transitioned from prednisone/EMFLAZA; 257 prescribers enrolled, targeting full conversion.
- **IP Defense**: FIRDAPSE patent litigation with Hetero set for March 2026 trial; no material changes from Markman hearing.
- **AGAMREE Royalties**: 5% of net sales up to $100M, 7% above, with $12.5M milestone payment due once annual revenue hits $100M.

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 total revenue up 19.4% YoY to $146.6 million, driven by FIRDAPSE (+9.7% YoY) and AGAMREE (+213% YoY). Full-year 2025 guidance reaffirmed at $545-565 million.
- **FIRDAPSE Expansion**: 16.9% H1 2025 growth to $168.6 million, with 90%+ prescription approval rates. Oncology-focused strategy targeting undiagnosed cancer-associated LEMS patients expected to boost 2026+ growth.
- **AGAMREE Momentum**: 93% DMD center engagement, 85% reimbursement success, and 43% patient transitions from steroids. Full-year 2025 guidance at $100-110 million.
- **FYCOMPA Challenges**: 6% YoY decline due to generic competition, with full-year guidance unchanged at $90-95 million.
- **Financial Strength**: Q2 2025 non-GAAP EPS $0.68, cash position $652.8 million, supporting strategic initiatives.

**【CEO Summary Section】**
- **Record Q2 2025 Performance**: Total revenue reached $146.6 million, up 19.4% YoY, with H1 2025 revenue at $288 million (+30.2% YoY). FIRDAPSE net product revenue was $84.8 million (+9.7% YoY), AGAMREE $27.4 million (+213% YoY), and FYCOMPA $34.3 million (-6% YoY). Full-year 2025 guidance remains $545-565 million.
- **FIRDAPSE Growth Drivers**: 16.9% H1 2025 growth to $168.6 million, with 90%+ prescription approval rates. Expansion strategy includes NCCN guideline updates, oncology-focused education, and VGCC antibody testing access. 2026+ growth expected from undiagnosed cancer-associated LEMS patients.
- **AGAMREE Momentum**: 93% of top DMD centers engaged, 85% reimbursement success, and 43% patient transitions from prednisone/EMFLAZA. Full-year 2025 guidance reaffirmed at $100-110 million.
- **FYCOMPA Challenges**: 6% YoY decline due to generic competition, with full-year guidance unchanged at $90-95 million.
- **Strategic Initiatives**: New CMO Will Andrews leading AGAMREE real-world evidence studies; 2025 ESG report published; patent litigation with first filers expected in Q4 2025/Q1 2026.

**【CFO Financial Commentary】**
- **GAAP Results**: Q2 2025 net income $52.1 million (+27.7% YoY), EPS $0.41. H1 2025 effective tax rate 22.6%.
- **Non-GAAP Metrics**: Q2 2025 non-GAAP net income $86.4 million (+24.2% YoY), EPS $0.68.
- **Cost Structure**: SG&A $45.9 million (+12.8% YoY) due to sales force expansion; R&D $4.4 million (+46% YoY) for AGAMREE studies.
- **Cash Position**: $652.8 million at Q2 end, up $135.2 million YoY, supporting strategic initiatives.

**【Q&A Highlights】**
- **FIRDAPSE Oncology Strategy**: Frictionless VGCC testing, NCCN guideline updates, and care pathway partnerships targeting 90% undiagnosed cancer-associated LEMS patients. Growth expected in 2026+.
- **AGAMREE Switching Study**: Phase I data expected late 2025/early 2026 to inform switching algorithms and life cycle management.
- **FYCOMPA Generic Impact**: Teva's 180-day exclusivity may limit near-term erosion, but additional generics expected by Q4 2025.
- **Manufacturing Strategy**: AGAMREE U.S. manufacturing transition underway to mitigate tariffs; FIRDAPSE production in U.S./Canada remains tariff-protected.
- **Business Development**: Actively evaluating opportunities in rare diseases, with 80% of pipeline inbound. Focus on assets aligning with long-term portfolio strategy.

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript

- **Q1 Revenue Surge**: $141.4 million total revenue (+43.6% YoY), driven by FIRDAPSE (+25.3%), AGAMREE (+1,733x YoY), and FYCOMPA (+17.1%).
- **FIRDAPSE Leadership**: 90%+ prescription approvals, 15% YoY growth, and 100mg dose expansion boosting adherence.
- **AGAMREE Momentum**: 93% DMD center engagement, 85% reimbursement success, and $100–110 million 2025 forecast.
- **FYCOMPA Transition**: 85% tablet dominance, 2025 guidance of $90–95 million despite May 2025 generic entry.
- **Cash Flexibility**: $580.7 million to fund R&D, international expansion, and strategic acquisitions.

**【CEO Opening Remarks】**
- Total net revenue for Q1 2025 reached $141.4 million, up 43.6% YoY, driven by strong performance across all products.
- FIRDAPSE revenue grew 25.3% YoY to $83.7 million, fueled by new patient starts and a 100mg dose expansion.
- AGAMREE delivered $22 million in Q1, marking its first full year of commercialization with 93% of top DMD centers engaged.
- FYCOMPA revenue rose 17.1% YoY to $35.6 million, despite nearing generic entry on May 23, 2025.
- Full-year 2025 revenue guidance reaffirmed at $545–565 million.

**【Chief Commercial Officer Highlights】**
- FIRDAPSE maintains 90%+ prescription approval rates, with 500+ pipeline patients representing 50% of quarterly new starts.
- AGAMREE transitions 44% of patients from prednisone and 44% from Emflaza, with 85% successful reimbursements.
- FYCOMPA expects a measured decline post-patent expiry, with 2025 guidance of $90–95 million.
- Commercial restructuring enhances focus on FIRDAPSE and AGAMREE with dedicated sales teams.

**【CFO Financial Breakdown】**
- GAAP net income of $56.7 million ($0.47 EPS) and non-GAAP EPS of $0.71, both exceeding expectations.
- Cost of sales rose to $17.9 million due to AGAMREE royalties, with potential $12.5 million milestone payment pending.
- R&D expenses increased to $3.9 million, supporting the SUMMIT Study and future label expansion efforts.
- Cash reserves of $580.7 million provide flexibility for strategic initiatives and business development.

**【Q&A Key Takeaways】**
- FIRDAPSE growth excludes Change Healthcare impact, maintaining 15–20% YoY target.
- FYCOMPA tablet/suspension split is 85%/15%, with plans to minimize brand erosion post-generic entry.
- Cancer-associated LEMS diagnosis initiatives aim to address 90% of undiagnosed small cell lung cancer patients.
- Business development remains disciplined, prioritizing accretive rare disease assets in a volatile market.
- AGAMREE's SUMMIT Study focuses on long-term bone health and cardiomyopathy outcomes in DMD patients.

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript

- **Record 2024 Growth**: Total revenue up 23.5% to $491.7 million, driven by FIRDAPSE (+18.4%), AGAMREE ($46M first year), and FYCOMPA ($137.3M). Q4 revenue hit $141.8M (+28.3% YoY).
- **2025 Outlook**: $545-$565M revenue target, with FIRDAPSE on track for >15% growth and AGAMREE targeting $100-$110M.
- **Strong Cash Position**: $517.6M cash at year-end, no debt, supporting strategic initiatives.
- **AGAMREE Momentum**: 93% DMD COE adoption, 44% Prednisone transitions, and SUMMIT study underway for long-term data.
- **FYCOMPA Transition**: Expected generic entry in Q2 2025, with gradual revenue decline offset by patient retention strategies.
- **Strategic Focus**: Rare disease M&A, Japan expansion, and LEMS market penetration with 500+ undiagnosed patients.


**【CEO Summary Section】**
- Full-year 2024 total revenue reached $491.7 million, up 23.5% YoY, driven by FIRDAPSE (+18.4% to $306 million), AGAMREE ($46 million in first full year), and FYCOMPA ($137.3 million). Q4 2024 revenue hit $141.8 million, +28.3% YoY.
- 2025 revenue forecast: $545-$565 million, with FIRDAPSE targeting $355-$360 million (15%+ growth), AGAMREE $100-$110 million, and FYCOMPA $90-$95 million post-patent expiry.
- Strong cash position of $517.6 million at year-end, no debt.
- FIRDAPSE shows 14 consecutive quarters of >15% YoY growth, with 90%+ prescription approval rates and <15% patient discontinuation rate.
- AGAMREE adopted in 93% of top 45 DMD Centers of Excellence, with 44% of new patients transitioning from Prednisone and 43% from EMFLAZA.
- FYCOMPA expected to face generic competition in Q2 2025, with gradual revenue decline anticipated.
- $81.5 million IPR&D expense in 2023 for AGAMREE acquisition impacts non-GAAP metrics.

**【CFO Financial Commentary】**
- 2024 GAAP net income: $163.9 million ($1.38 EPS), +130% YoY. Non-GAAP net income: $276.3 million ($2.33 EPS), +95% YoY.
- R&D expenses declined to $12.6 million (vs. $93.2 million in 2023 due to one-time AGAMREE IPR&D charge).
- SG&A expenses rose to $177.7 million (+33% YoY) to support AGAMREE launch and commercial expansion.
- 2025 guidance: FIRDAPSE net product revenue $355-$360 million (including IRA-related gross-to-net increases), AGAMREE $100-$110 million, FYCOMPA $90-$95 million.
- Cash flow provided by operations: $240 million in 2024, with $380 million total cash increase.

**【Q&A Highlights】**
- **FIRDAPSE pipeline**: 500+ diagnosed LEMS patients not yet on therapy, contributing ~50% of new enrollments monthly.
- **AGAMREE adoption**: SUMMIT study to generate real-world data on long-term benefits; 20% of patients on 100mg dose post-label expansion.
- **FYCOMPA strategy**: Personalized patient support and payer contracting to mitigate generic erosion.
- **M&A focus**: Rare disease assets with clinical differentiation and clear commercialization paths; cautious on gene therapy due to CMC challenges.
- **Japan expansion**: FIRDAPSE launched by sublicensee DyDo in Q1 2025, with potential for global partner network.
- **IRA impact**: 2025 FIRDAPSE gross-to-net rate expected to increase 3-3.5% annually, offsetting revenue growth.
- **Cancer-associated LEMS**: 90% of small cell lung cancer LEMS patients undiagnosed; field force pivot to community oncologists in 2025.


Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript

Catalyst Pharmaceuticals (CPRX)-7 Nov 24-2024 Q3 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-8 Aug 24-2024 Q2 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-9 May 24-2024 Q1 Earnings call transcript

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript

Catalyst Pharmaceuticals (CPRX)-9 Nov 23-2023 Q3 Earnings call transcript

- **Revenue Record**: Q2 2023 revenue of $99.6 million (+87.5% YoY), driven by FIRDAPSE (+22.3%) and FYCOMPA ($34.6M first full quarter)
- **Vamorolone Milestone**: $75M one-time R&D charge, PDUFA date October 26, 2023 for Duchenne Muscular Dystrophy
- **Global Expansion**: Japan NDA submission for FIRDAPSE by year-end, targeting China/S. Korea expansion
- **FYCOMPA Integration**: 45% prescriber overlap with FIRDAPSE, early adoption trends positive
- **Financial Strength**: $178.8M cash, updated 2023 guidance raised to $380-390M

**【CEO Summary Section】**
- Total Q2 2023 revenue: $99.6 million (87.5% YoY growth)
- FIRDAPSE net revenue: $64.9 million (22.3% YoY growth)
- FYCOMPA net revenue: $34.6 million (first full quarter contribution)
- Vamorolone acquisition: $75 million one-time R&D charge, PDUFA date October 26, 2023
- Updated 2023 revenue guidance: $380-390 million
- Japan NDA submission for FIRDAPSE expected by end of 2023
- Global expansion plans for FIRDAPSE in China, South Korea, etc.

**【CFO Financial Commentary】**
- GAAP net income: $37.8 million ($0.36/basic, $0.33/diluted)
- Non-GAAP net income: $60.4 million ($0.57/basic, $0.53/diluted)
- Cash and equivalents: $178.8 million (pre-Vamorolone acquisition)
- R&D expenses: $4 million (Q2), +$75 million one-time charge in Q3
- SG&A expenses: $28.4 million (54% of total operating expenses)
- Royalty rate increase to 3% for FIRDAPSE sales >$100 million/year

**【Q&A Highlights】**
- **FIRDAPSE Lead Pipeline**: 450+ undiagnosed LEMS patients, 50% new enrollments from this pool
- **Tumor LEMS Growth**: 25% of new FIRDAPSE starts in Q2 from small cell lung cancer patients
- **Vamorolone Launch**: <10 new sales reps needed, commercial launch Q1 2024 if approved
- **FYCOMPA Synergies**: 45% overlap in prescribers with FIRDAPSE, early adoption trends positive
- **Gross Margin Stability**: Expect ~88% margins to hold in second half of 2023

Catalyst Pharmaceuticals (CPRX)-10 Aug 23-2023 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2023 revenue up 98% YoY to $85.4 million, driven by Firdapse (+34%) and Fycompa. 
- **Guidance Confirmed**: 2023 targets: $375-385M revenue, $195-205M non-GAAP net income. 
- **Strategic Moves**: 
  - Fycompa U.S. launch on track for $130M annual sales. 
  - Japan Firdapse NDA submission Q2 2024. 
  - FDA 100mg dose expansion SNDA Q3 2023. 
- **Financial Strength**: $148M cash, 2023 operating expenses guided at $160-170M. 
- **LEMS Penetration**: 25% diagnosed patients on Firdapse; 80% small cell lung cancer LEMS patients undiagnosed.

**【CEO Summary Section】**
- Total Q1 2023 revenue: $85.4 million (98% YoY growth), driven by Firdapse ($57.5 million, +34% YoY) and Fycompa ($27.8 million for 2 months). 
- Reaffirmed 2023 guidance: $375-385 million total revenue (+75%-80% YoY), $195-205 million non-GAAP net income. 
- Fycompa U.S. rights acquisition completed in January; full commercial team deployed in May. 
- Global expansion plans include Japan (Phase III completion by end-2023, NDA submission Q2 2024) and Latin America. 
- Seeking FDA approval to increase Firdapse max daily dose from 80mg to 100mg via SNDA submission Q3 2023. 

**【CFO Financial Commentary】**
- GAAP net income: $29.6 million (Q1 2023 vs. $13.2 million Q1 2022). 
- Non-GAAP net income: $46.8 million (Q1 2023 vs. $19.4 million Q1 2022). 
- Cash position: $148 million (post $160 million Fycompa acquisition). 
- 2023 operating expenses guidance: $160-170 million (includes $32 million amortization). 
- Fycompa-related expenses: $40-45 million/year. 

**【Q&A Highlights】**
- **Firdapse Seasonality**: Q1 impacted by patient re-authorization delays and rebate resets, but 2023 guidance unchanged. 
- **Fycompa Run Rate**: 2-month Q1 sales of $27.8 million suggest annualized $130 million target achievable. 
- **LEMS Penetration**: ~25% of diagnosed LEMS patients on Firdapse; 80% of small cell lung cancer LEMS patients undiagnosed. 
- **Dose Expansion**: 40% of patients on 80mg+ dose; SNDA for 100mg max dose expected Q3 2023. 
- **Global Strategy**: Japan partnership model for Asia expansion; 7 rare epilepsies identified for Fycompa use. 
- **Oncology Outreach**: 25% of new Firdapse enrollments from tumor LEMS patients; targeting top 30 thoracic oncology centers.

Catalyst Pharmaceuticals (CPRX)-11 May 23-2023 Q1 Earnings call transcript

- **Revenue Growth**: 2022 total net revenue $214 million (52% YoY), Q4 $61 million (59% YoY), 2023 guidance $375-$385 million.
- **FYCOMPA Acquisition**: $130 million 2023 contribution, integration by mid-2023 with 6,700 target prescribers.
- **FIRDAPSE Momentum**: 25% LEMS patient penetration, 1,000 unique patients, 2023 net revenue $245-$255 million.
- **Financial Strength**: $298 million cash, 2022 GAAP net income $83 million, 2023 tax rate 23%-25%.
- **Strategic Moves**: 100mg FIRDAPSE NDA filing Q3 2023, Japan Phase III trial completion Q4 2023.

**【CEO Opening Remarks】**
- Full year 2022 total net revenue: $214 million (52% YoY growth), Q4 net revenue: $61 million (59% YoY growth).
- GAAP net income: $83 million (110% YoY increase), Non-GAAP EPS: $1.10 (93% YoY increase).
- FYCOMPA acquisition completed in January 2023, expected to contribute $130 million in 2023 net revenue.
- 2023 guidance: Total net revenue $375-$385 million (75%-80% YoY growth), FIRDAPSE $245-$255 million, FYCOMPA $130 million.
- Ended 2022 with $298 million in cash and no debt.

**【CFO Financial Commentary】**
- GAAP net income: $83.1 million (21% effective tax rate), Non-GAAP net income: $113.1 million.
- Cost of sales: $34.4 million (16% of product revenue), R&D: $19.8 million (18% of operating expenses), SG&A: $58.2 million (52% of operating expenses).
- 2023 cash position: $298 million, with $162 million used for FYCOMPA acquisition.
- Anticipated 2023 tax rate: 23%-25%.

**【CFO Financial Commentary】**
- GAAP net income: $83.1 million (21% effective tax rate), Non-GAAP net income: $113.1 million.
- Cost of sales: $34.4 million (16% of product revenue), R&D: $19.8 million (18% of operating expenses), SG&A: $58.2 million (52% of operating expenses).
- 2023 cash position: $298 million, with $162 million used for FYCOMPA acquisition.
- Anticipated 2023 tax rate: 23%-25%.

**【Q&A Highlights】**
- **FIRDAPSE Penetration**: 25% of estimated 3,000 LEMS patients, 1,000 unique patients enrolled since launch.
- **FYCOMPA Strategy**: 6,700 target prescribers, 45% overlap with FIRDAPSE call points, integration by mid-2023.
- **Japan Regulatory Update**: Phase III trial completion expected Q4 2023, NDA submission in 2024, 1,200-1,300 LEMS patients in Japan.
- **100mg Dose**: Supplemental NDA filing planned Q3 2023, ~40% of patients on 80mg may transition to 100mg.
- **Interest Income**: ~4%-5% yield on $298 million cash, driven by 90-day T-bills.


Catalyst Pharmaceuticals (CPRX)-16 Mar 23-2022 Q4 Earnings call transcript

- **Revenue Growth**: Q3 revenue $57.2M (+59.3% YoY), full-year guidance raised to $205-210M.
- **Profitability**: Non-GAAP net income $28.6M, cash position $256M.
- **Strategic Initiatives**: Expanded oncology marketing, acquired Ruzurgi rights, pediatric Firdapse approval.
- **Pipeline**: Seeking 100mg/day Firdapse dose approval, Japan NDA filing in 2024.
- **Growth Drivers**: 85% QoQ new patient growth, 30% small cell lung cancer LEMS patients.

**【CEO Summary Section】**
- Reported Q3 2022 net product revenue of $57.2 million, a 59.3% YoY increase, driven by Firdapse sales growth.
- GAAP net income of $22.7 million ($0.22 basic share), non-GAAP net income of $28.6 million ($0.28 basic share).
- Raised full-year 2022 revenue guidance to $205-210 million (prev. $195-200M), with Q4 momentum strong.
- Cash position of $256.1 million, up $35.3M QoQ, supporting strategic initiatives.
- Expanded oncology-focused marketing to thoracic oncologists for LEMS patients with small cell lung cancer.
- Acquired Ruzurgi rights from Jacobus, adding two patents (total six in Orange Book) and extending IP to 2037.
- FDA approved pediatric Firdapse indication for patients ≥6 years old.
- Acquired Jacobus assets with $10M upfront payment, $20M in future milestone payments.

**【CFO Financial Commentary】**
- Cost of sales $9.7 million (17% of revenue), up from $5.3M (15%) due to royalty escalations.
- R&D expenses $8.3 million (4.1M from Ruzurgi inventory write-off), SG&A $14.2 million (25% of revenue).
- Amortization of $518K Q3 for Jacobus intangibles, with $580K/Q future amortization.
- Effective tax rate 19.7% (annualized), guided to 22-23% for 2022.
- Cash flow positive, with $256M in cash and investments.

**【Chief Commercial Officer Highlights】**
- Q3 new patient enrollments up 85% vs Q2, discontinuation rate down 35%.
- 30% of new enrollments are small cell lung cancer LEMS patients.
- 85%+ payer access, 90%+ compliance rate, <15% annual discontinuation rate.
- Targeting 35-40% of new enrollments from oncology channel in 2023.
- 50%+ increase in VGCC antibody tests in 2022, shortening diagnostic journey.

**【R&D & Regulatory Updates】**
- FDA approved pediatric Firdapse indication for patients ≥6 years old.
- Acquired two new patents (total six in Orange Book, expiring 2037).
- Ruzurgi supply to 100+ patients with CMS under INDs, evaluating long-term strategy.
- Seeking FDA approval to increase Firdapse max dose to 100mg/day.
- Japan Phase 3 trial enrollment complete, NDA filing expected Q1 2024.

**【Q&A Highlights】**
- 30% of new enrollments are small cell lung cancer LEMS patients, targeting 35-40% in 2023.
- Organic growth rate maintained at 15-20% annually.
- No plans to pursue CMS indication for Ruzurgi due to regulatory complexity.
- Prepared for potential patent challenges given Firdapse's >$200M annual sales.
- Interest income from $256M cash balance at 3.5-4% rates.

Catalyst Pharmaceuticals (CPRX)-10 Nov 22-2022 Q3 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-10 Aug 22-2022 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2022 net product revenue up 42.5% YoY to $43 million
- **Patient Transition Success**: 90%+ Ruzurgi patients switched to Firdapse with >95% payer approvals
- **New Patient Growth**: April 2022 naive enrollments match all-time high
- **Financial Strength**: $198 million cash, no debt, 25% effective tax rate
- **Pipeline Expansion**: 3 new Firdapse patents, Japan Phase 3 study progressing
- **Business Development**: Actively evaluating commercial-stage rare disease assets

**【CEO Opening Remarks】**
- Q1 2022 net product revenue: $43 million (42.5% YoY increase)
- GAAP net income: $13.2 million ($0.13 per share), 76.7% YoY growth
- Repurchased 400,000 shares in Q1, total $2.6 million shares repurchased since March 2021
- 125 Ruzurgi patients transitioned to Firdapse, 90%+ payer approval rate
- Full-year 2022 revenue guidance: $195-205 million (38-45% YoY growth)

**【CFO Financial Commentary】**
- GAAP net income: $13.2 million (72.8% YoY increase)
- Non-GAAP EPS: $0.19 (67.9% YoY increase)
- Cash and investments: $198 million
- Cost of sales: 14% of product revenue
- R&D expenses: $3.4 million (13% of total expenses)
- SG&A expenses: $16.4 million (64% of total expenses)
- Royalty rate to increase by 3% if annual sales exceed $100 million

**【Commercial Update】**
- 90%+ Ruzurgi patients transitioned to Firdapse by end of Q2
- Q1 naive new patient enrollments: 18% YoY increase
- April 2022 naive new enrollments match highest monthly total since launch
- 95%+ payer approval rate for transitions
- 3,000 estimated U.S. LEMS patients, 1,500 diagnosed but only 800 on Firdapse

**【R&D & IP Update】**
- 3 new patents issued for Firdapse, listed in FDA Orange Book
- U.S. patent protection extended to 2034
- sNDA filed for pediatric LEMS label expansion
- Japan Phase 3 study enrollment on track for 2023 completion

**【Q&A Highlights】**
- Transition accuracy: 125 patient estimate ±5%, 95%+ payer approvals
- Q2 growth drivers: Ruzurgi transition impact + organic new enrollments
- Business development: Actively evaluating commercial-stage assets
- Operating expenses: $65-70 million (excl. stock comp)
- Tax rate: ~25% annualized
- Royalty rate: 7% base + 3% if >$100M annual sales

Catalyst Pharmaceuticals (CPRX)-11 May 22-2022 Q1 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-17 Mar 22-2021 Q4 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-10 Nov 21-2021 Q3 Earnings call transcript

- **Revenue Growth**: Q2 2021 revenue up 23% YoY to $36.4M, driven by 14% YoY Firdapse sales growth
- **Share Buybacks**: $5.1M spent on 1M shares under $40M program
- **COVID Impact**: 15% below pre-pandemic neurology visit levels, but 25% lower patient discontinuations vs H1 2020
- **Pipeline Progress**: Long-acting Firdapse formulation study planned for 2021; 4 patents issued/pending
- **Strategic Acquisitions**: $155M cash balance to pursue rare disease assets outside oncology

**【CEO Summary Section】**
- Total net revenues for Q2 2021: $36.4 million (23% YoY growth), driven by $33.6 million in Firdapse product revenue (14% YoY growth). GAAP net income: $12.2 million ($0.12 per share), up 24% YoY. Cash and investments: $155.3 million.
- Completed DyDo Pharma agreement for Japan rights, contributing $2.7 million in revenue. Opened share repurchase program, buying 1M shares ($5.1 million spent so far). 
- COVID-19 continues to impact physician practices and patient access, but expect recovery in H2 2021. Hired Dr. Preethi Sundaram (Chief Product Dev Officer) and Molly Harper (Board member) to strengthen leadership.

**【CFO Financial Commentary】**
- Q2 2021: 
  - Total revenue: $36.4M (23% YoY)
  - Firdapse product revenue: $33.6M (14% YoY)
  - GAAP net income: $12.2M ($0.12/share) vs $9.8M ($0.09/share) in Q2 2020
  - Non-GAAP net income: $17.4M ($0.17/share)
  - Cash: $155.3M (down $3.7M for share buybacks)
- Tax rate: 22% (vs 5.7% in Q2 2020 due to NOL usage)
- R&D expenses: $4.5M (stable vs Q2 2020)
- SG&A expenses: $11.5M (6% YoY growth)

**【Commercial Update】**
- Q2 2021 Firdapse performance:
  - New patient enrollments: 111% YoY growth
  - 90-day discontinuation rate: <15% (25% lower than H1 2020)
  - Prescription approval rate: >90%
  - Avg copay for Medicare patients: <$2/month
- COVID-19 impact: 15% below pre-pandemic neurology visit levels, but 20,000+ HCPs engaged (50% in-person)
- Patient resources: 1,900+ opt-ins for educational materials

**【R&D Update】**
- Long-acting Firdapse:
  - Completed PK study in Q4 2020, 3 formulations under evaluation
  - Additional PK study planned for 2021
  - Targeting pre-COVID patient demand for convenience
- MuSK-MG trial:
  - FDA questions study design, expert panel review ongoing
  - Previous studies show positive feedback from patients/doctors
- Intellectual property:
  - 4 patents issued/pending to protect Firdapse franchise
  - Lawsuit against Jacobus Pharmaceuticals for patent infringement

**【Q&A Highlights】**
1. **Commercial Strategy**:
   - Patient resources (e.g., VGCC test, CME courses) shorten diagnostic journey
   - 1,900+ patient/caregiver opt-ins for educational materials
   - 4,000+ HCPs completed LEMS CME course
2. **Pipeline Timing**:
   - Long-acting Firdapse: ~1 year of formulation work remaining
   - Aim to launch before orphan drug exclusivity expires
3. **Acquisition Strategy**:
   - Prefer rare disease assets with validated technology
   - Potential to leverage existing sales force or build new teams
   - Focus outside oncology, e.g., endocrinology
   - $155M cash balance + $10-15M quarterly cash flow provides flexibility

Catalyst Pharmaceuticals (CPRX)-10 Aug 21-2021 Q2 Earnings call transcript

- **Revenue Resilience**: $30.2 million Q1 revenue (+4% YoY) despite COVID-19 impact on diagnostic visits.
- **Patient Growth**: 15% QoQ increase in new patient starts; 90% of new prescribers first-time Firdapse users.
- **Financial Strength**: $143.3 million cash; $40 million share buyback program underway.
- **R&D Momentum**: New MuSK-MG trial design submitted; HNPP trial Q3 2021; Japan regulatory path established.
- **Litigation Update**: Waiting on Canadian court decision; U.S. patent infringement case ongoing.
- **Strategic Expansion**: Evaluating rare disease acquisitions outside oncology.

**【Management Opening Remarks】**
- CEO Patrick McEnany highlighted Q1 2021 revenue of $30.2 million, a 4% YoY increase despite COVID-19 challenges.
- Emphasized ongoing recovery in physician visits and new patient enrollments, with 15% growth in Q1 new patient starts vs. Q4 2020.
- Announced a $40 million share buyback program, with 507,555 shares repurchased at an average price of $4.49.
- Highlighted $143.3 million in cash and investments, with no debt.

**【CEO Commentary】**
- Q1 revenue growth driven by new patient enrollments, despite 12% lower diagnostic visits vs. pre-COVID levels.
- Discussed ongoing litigation with FDA over Ruzurgi orphan exclusivity and Jacobus Pharmaceuticals patent infringement.
- Updated on business development efforts, targeting rare disease therapies outside oncology.

**【CFO Financial Commentary】**
- GAAP net income: $7.7 million ($0.07/share); Non-GAAP net income: $11.6 million ($0.11/share).
- $2 million Q1 charge for patient assistance programs; effective tax rate 22.5% vs. 5.4% in Q1 2020.
- R&D expenses: $3 million (29% YoY decline); SG&A: $12.7 million (26% YoY increase due to litigation and personnel costs).

**【Q&A Highlights】**
- **Patient Growth**: 90% of new prescribers are first-time Firdapse users; 15% QoQ increase in new patient starts.
- **Litigation Update**: Waiting on Canadian Federal Court decision on Ruzurgi; U.S. patent litigation with Jacobus ongoing.
- **Pipeline Progress**: New MuSK-MG trial design submitted to FDA; HNPP trial expected Q3 2021.
- **Japan Strategy**: Seeking partner for Firdapse launch in Japan, targeting 1,200-1,300 LEMS patients.
- **Share Buyback**: No accelerated program; purchases based on market conditions and strategic priorities.

Catalyst Pharmaceuticals (CPRX)-11 May 21-2021 Q1 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-16 Mar 21-2020 Q4 Earnings call transcript

- **Q3 Financial Strength**: $29.2M revenue, $127.1M cash, 15% discontinuation rate.
- **Patient Recovery**: Q3 new enrollments up 200% vs Q2; October highest since 2019.
- **Global Expansion**: Canada launch, Japan partnership; 1,200 LEMS patients in Japan.
- **Legal Battles**: Appeal against FDA decision; lawsuits for patent infringement.
- **Pipeline Progress**: SMA Type 3 trial results Q4; long-acting Firdapse in development.

**【CEO Opening Remarks】**
- Q3 2020 product revenue: $29.2M, net income from operations: $11.6M, cash flow from operations: $13M.
- Cash balance: $127.1M with no debt.
- New patient enrollments improved in Q3, September/October showing strongest trends since Q2 2019.
- 90-day discontinuation rate: ~15%, minimal defections to Ruzurgi.
- Firdapse approved in Canada (partner: Kai Pharmaceuticals) and progressing for Japan approval.
- Legal actions: Appeal filed against FDA decision; lawsuits for patent infringement and data exclusivity in Canada.

**【CFO Financial Commentary】**
- GAAP net income: $43.3M ($0.42/share), non-GAAP net income: $44.8M ($0.43/share).
- Product revenue: $29.2M (down 6% YoY), cost of sales: $3.9M.
- R&D expenses: $3.8M (down 17% YoY), SG&A: $10M (up 23% YoY).
- Cash: $127.1M; no debt.

**【Commercial Update (Jeffrey Del Carmen)】**
- Q3 new patient enrollments up vs Q2, October highest since July 2019.
- 90-day compliance >90%, co-pay <$2/month for Medicare patients.
- Canada launch: ~300-400 LEMS patients; Japan: ~1,200 patients.
- Global strategy: Expand commercial infrastructure, explore partnerships.

**【R&D & Pipeline Update (Steven Miller)】**
- MuSK-MG trial: Mixed results (improvement in open-label vs randomized phases).
- SMA Type 3 trial: Top-line results expected Q4 2020.
- Long-acting Firdapse: PK study completed, formulation development ongoing.
- Japan: Regulatory agreement; small clinical trial planned.
- Patents: New U.S. patent (expires 2034) listed in Orange Book.

**【Q&A Highlights】**
- **Market Expansion**: Canada (~10% U.S. market), Japan (~40% U.S. market). Pricing expected lower than U.S.
- **Trial Analysis**: MuSK-MG trial anomaly likely trial design-related; analysis ongoing.
- **Patient Trends**: October enrollments highest since July 2019; cautious optimism for Q4.
- **R&D Costs**: ~$3.8M/Q3; similar 2021 outlook.
- **Corporate Strategy**: Evaluate acquisitions of late-stage assets; explore rare disease bolt-ons.

Catalyst Pharmaceuticals (CPRX)-10 Nov 20-2020 Q3 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-11 Aug 20-2020 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2020 revenue up 134% YoY to $29.1 million, despite COVID-19-related new patient decline.
- **Supply Chain Resilience**: 18-month Firdapse inventory and API stock through 2023; no patient supply gaps.
- **Clinical Trial Delays**: MuSK MG Phase 3 top-line data pushed to Q3; SMA Type 3 trial delayed in Serbia.
- **Financial Strength**: $101.8 million cash; GAAP net income $10.4 million.
- **Virtual Engagement**: 90% prescription approval rate maintained via digital tools despite 70% physician visit drop.

**【CEO Opening Remarks】**
- Q1 2020 revenue: $29.1 million (134% YoY growth), driven by Firdapse launch.
- Withdrawn 2020 guidance due to COVID-19 uncertainty; Q2 new patient starts expected to decline by ~70%.
- Stable supply chain with 18-month Firdapse inventory and API stock through 2023.
- $101.8 million cash on hand; no debt.

**【CFO Financial Commentary】**
- GAAP net income: $10.4 million ($0.10 EPS); non-GAAP EPS: $0.12.
- R&D expenses: $4.2 million (up 27% YoY); SG&A: $10.1 million (20% YoY growth).
- Gross margin improvement from pre-launch manufacturing.

**【CCO Commercial Update】**
- 46 new Firdapse patients (total 575); 90-day discontinuation rate <20%.
- Virtual engagement tools (emails, videos) maintain patient access despite 70% drop in physician visits.
- 90% prescription approval rate; $1.09/month average co-pay.

**【COO Clinical Update】**
- MuSK MG Phase 3 trial completed; top-line data delayed to Q3 2020.
- SMA Type 3 trial delayed in Serbia; top-line data expected late 2020.
- Long-acting Firdapse formulation development underway.
- Canada NDS for LEMS granted priority review; Japan regulatory discussions delayed.

**【Q&A Highlights】**
- Q2 revenue impact from ~$1 million of Q1 forward purchasing; no material supply chain disruption.
- Virtual salesforce engagement strategies show promise despite physician visit decline.
- Cautious optimism for MuSK MG trial success due to disease homogeneity.
- Business development focused on late-stage neuromuscular assets at attractive valuations.

Catalyst Pharmaceuticals (CPRX)-12 May 20-2020 Q1 Earnings call transcript

- **Revenue Growth**: 2019 net revenue $102 million; 2020 guidance $135-155 million, driven by new LEMS patient starts (35% diagnosed untreated).
- **Supply Chain Resilience**: U.S.-based manufacturing with 6-month safety stock to mitigate COVID-19 risks.
- **Clinical Momentum**: Phase III MuSK-MG trial on track for Q2 results; SMA Type 3 trial ongoing.
- **Global Expansion**: Canada NDS submission (priority review); Japan regulatory discussions.
- **Financial Health**: 2019 GAAP net income $32 million; cash balance $94.5 million.

**【CEO Opening Remarks】**
- 2019 was transformative, with Firdapse launch exceeding expectations, achieving $102 million in net revenue. 2020 guidance set at $135-155 million.
- Emphasized supply chain resilience against COVID-19, with U.S.-based manufacturing and 6-month safety stock.
- Phase III MuSK-MG trial completed enrollment, targeting 3,000-4,800 U.S. patients, with topline results expected Q2 2020.
- Global expansion efforts include Canada NDS submission (priority review) and Japan regulatory discussions.

**【Commercial Update】**
- 532 patients prescribed Firdapse as of Q4, with 35% of diagnosed LEMS patients on therapy.
- Average co-pay reduced to $1.08/month, 94% of patients with zero out-of-pocket costs.
- Discontinuation rate for new patients improved to 25% (from 35%), aligning with clinical trial experience.
- Expanded commercial efforts: doubled salesforce, telesales partnership (15+ leads in 5 weeks), and digital media campaigns.

**【Clinical Pipeline Update】**
- Phase III MuSK-MG trial completed enrollment, with cautious optimism for Q2 results.
- SMA Type 3 trial ongoing in Italy/Eastern Europe, targeting 12 patients.
- Discontinued CMS trial due to lack of efficacy in heterogeneous population.
- Long-acting Firdapse formulation in development for reduced dosing frequency.

**【CFO Financial Review】**
- 2019 GAAP net income: $32 million; non-GAAP: $35.7 million.
- Q4 2019 revenue: $30.1 million; full-year R&D: $18.8 million; SG&A: $36.9 million.
- 2020 expenses expected to rise due to clinical trials, commercial expansion, and FDA lawsuit.
- Cash balance: $94.5 million as of December 31, 2019.

**【Q&A Highlights】**
- Guidance drivers: new patient starts (35% diagnosed LEMS untreated), persistence rates, and expanded salesforce.
- COVID-19 impact: field teams working remotely, specialty pharmacy ensuring drug delivery.
- MuSK-MG trial cautious optimism due to homogeneous patient population and successful proof-of-concept.
- Canada partnership sought for rare disease expertise; Japan regulatory path under discussion.
- 2020 COGS expected to increase due to post-approval manufacturing costs, but not significantly impacting margins.

Catalyst Pharmaceuticals (CPRX)-17 Mar 20-2019 Q4 Earnings call transcript

- **Revenue Guidance Confirmed**: 2019 at $100M, 2020 $135-155M, driven by Firdapse adoption (30% of LEMS patients treated).
- **Clinical Progress**: CMS-001 trial shows individual responses; MuSK-MG Phase 3 on track for 2020 readout.
- **Global Expansion**: Canada NDS filed (priority review), Japan regulatory discussions.
- **Financial Strength**: $81.6M cash, Q3 net income $13.6M, Firdapse revenue $30.9M.
- **Q4 Caution**: Slower growth due to patient transitions, but 2020 poised for acceleration with expanded sales force.

**【CEO Summary Section】**
- Provided full-year 2019 revenue guidance of $100 million and 2020 guidance of $135-155 million, reflecting strong Firdapse launch momentum.
- Firdapse has been prescribed to 490 patients as of Q3, with 30% of diagnosed adult LEMS population treated.
- CMS-001 Phase 3 trial did not meet statistical significance but showed individual patient responses; FDA meeting scheduled for end of 2019.
- Expanded commercial footprint with Canada NDS filing (priority review) and Japan regulatory discussions.
- Planning to add 10 regional account managers and 7-10 inside sales reps to target 9,000 neurologists.

**【CFO Financial Commentary】**
- Q3 2019 net income: $13.6 million ($0.13/share) vs. Q3 2018 loss of $7.8 million.
- Firdapse net product revenue: $30.9 million; R&D expenses: $4.6 million; SG&A: $8.1 million.
- Cash and investments: $81.6 million as of September 30, 2019 (no debt).

**【Q&A Highlights】**
- Q4 2019 expected to be slower due to patient transitions and discontinuations, but 2020 growth driven by expanded sales force.
- CMS-001 trial data to be published in 2020; MuSK-MG Phase 3 trial on track for H1 2020 readout.
- Ruzurgi competition limited to ~20 patients; Firdapse maintains 95% insurance approval rate and $1.66/month co-pay.
- Tax analysis underway; no immediate impact on EPS expected.

Catalyst Pharmaceuticals (CPRX)-13 Nov 19-2019 Q3 Earnings call transcript

Catalyst Pharmaceuticals (CPRX)-8 Aug 19-2019 Q2 Earnings call transcript

- **Firdapse Launch Success**: 250+ patients treated and 165 prescribers within 2 months, with 50%+ paying $0/month.
- **Clinical Pipeline Momentum**: CMS and MuSK-MG Phase 3 trials on track for 2019 readouts; SMA Type 3 trial initiated.
- **Financial Stability**: $58.5M cash balance supports operations; 2018 R&D/G&A expenses reflect pre-launch investments.
- **Payer Support**: Over 25 major payers covering Firdapse, with faster-than-expected reimbursement.

**【CEO Opening Remarks】**
- Announced the successful commercial launch of Firdapse on January 15, 2019, marking the first FDA-approved treatment for LEMS.
- Highlighted three strategic priorities: Firdapse launch execution, clinical trials for CMS, MuSK-MG, and SMA Type 3, and development of a long-acting Firdapse formulation.
- Reported 250+ patients treated and 165 unique prescribers as of March 15, 2019, with 39 patients accessing Firdapse for the first time.
- Noted strong payer coverage, with over 50% of patients paying $0/month and average co-pay <$10/month.

**【CFO Financial Commentary】**
- 2018 GAAP net loss: $34 million (vs. $18.4 million in 2017); 2018 R&D expenses: $19.9 million (vs. $11.4 million in 2017).
- 2018 G&A expenses: $15.9 million (vs. $7.3 million in 2017), driven by pre-commercialization costs.
- Ended 2018 with $58.5 million in cash, sufficient for 12+ months of operations.

**【COO Clinical Update】**
- CMS Phase 3 trial on track for H2 2019 readout; MuSK-MG Phase 3 trial with 29 sites enrolling for H2 2019 readout.
- SMA Type 3 proof-of-concept trial initiated Q1 2019, targeting H1 2020 readout.
- Expanded Access Program providing Firdapse to CMS and MuSK-MG patients at no cost.

**【Q&A Highlights】**
- **Prescriber Diversity**: 165 prescribers include neurologists outside initial centers, with 39 patients newly accessing Firdapse.
- **Patient Persistence**: Early feedback positive; co-pay support reduces financial burden.
- **Market Access**: 25+ major payers (e.g., Express Scripts, Cigna) covering Firdapse, with faster-than-expected reimbursement times.
- **Clinical Trials**: CMS and MuSK-MG trials progressing well; long-acting Firdapse development underway but no timeline disclosed.

Catalyst Pharmaceuticals (CPRX)-19 Mar 19-2018 Q4 Earnings call transcript

- **FDA Approval Imminent**: Anticipating November 28 PDUFA decision for Firdapse NDA; Canada launch discussions pending U.S. approval.
- **Commercial Readiness**: 25+ sales reps and patient liaisons hired; Catalyst Pathways program ensures seamless EAP transition and affordable access.
- **Clinical Pipeline Progress**: CMS Phase III trial enrollment delayed; SMA Type 3 proof-of-concept trial underway; long-acting Firdapse development planned.
- **Financial Position**: $66.7 million cash; R&D and G&A expenses up 67% and 125% YoY, reflecting pre-launch investments.

**【CEO Summary Section】**
- Catalyst reported successful execution of 2018 strategic priorities, including preparation for Firdapse launch in early 2019.
- Key initiatives: commercial readiness for LEMS treatment, clinical trials for CMS, MuSK MG, and SMA Type 3, and FDA approval pursuit for Canada.
- Expanded access program (EAP) transition plan ensures seamless patient access post-launch.
- Hired senior commercial leadership (Dan Brennan, Jeff Del Carmen, Jason James) to support launch.

**【CFO Financial Commentary】**
- Q3 2018 GAAP net loss: $7.8 million ($0.08 per share) vs. $4.2 million ($0.05 per share) in Q3 2017.
- R&D expenses: $4.5 million (vs. $2.7 million in 2017), driven by NDA submission costs, clinical trials, and headcount expansion.
- G&A expenses: $3.6 million (vs. $1.6 million in 2017), due to pre-commercialization costs and infrastructure build.
- Cash and investments: $66.7 million, sufficient for 2019 operations without revenue.

**【Q&A Highlights】**
- **FDA Interactions**: No outstanding requests; final labeling discussions ongoing. Transition of ~250-300 EAP patients to commercial product expected within 30-90 days.
- **CMS Trial Delays**: Enrollment in Phase III CMS trial (pediatric safety data collection) delayed due to rare mutations and recruitment challenges.
- **Commercial Infrastructure**: Hiring 25+ sales reps and patient liaisons; Catalyst Pathways program includes dosing guidance, co-pay assistance, and insurance navigation.
- **Long-Acting Firdapse**: Development to begin post-U.S. approval, targeting improved compliance and potential efficacy benefits (e.g., overnight symptom relief).

Actual											0.1	0.09	0.41	0.11	0.07	0.11	0.1	0.09	0.12	0.2	0.2	0.22	0.26	0.33	-0.29	0.31	0.19	0.33	0.35	0.44	0.45	0.41	0.42	0.41	0.5
Forecast											0.0867	0.085	0.096	0.09	0.086	0.096	0.104	0.116	0.136	0.17	0.19	0.21	0.322	0.254	-0.3	0.265	0.1983	0.228	0.304	0.3386	0.34	0.392	0.332	0.344	0.475
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+15.34%	+5.88%	+327.08%	+22.22%	-18.60%	+14.58%	-3.85%	-22.41%	-11.76%	+17.65%	+5.26%	+4.76%	-19.25%	+29.92%	+3.33%	+16.98%	-4.19%	+44.74%	+15.13%	+29.95%	+32.35%	+4.59%	+26.51%	+19.19%	+5.26%

CPRX(Quitar la ciudad)

CPRX(Quitar la ciudad)

Catalyst (CPRX) Earnings

CPRX Q1 2026 Earnings

EPS

Revenue

Earnings Call

You can ask Aime